# ACTICCA-1 (NCT02170090)

> Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer

No report yet. It can be ordered.

- Drugs tested: gemcitabine plus cisplatin
- Indication: biliary tract cancer after curative intent resection

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02170090
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Universitätsklinikum Hamburg-Eppendorf
- Conditions: Cholangiocarcinoma; Gall Bladder Carcinoma
- Interventions: Gemcitabine; Cisplatin; Capecitabine
- Enrollment: 789
- Primary outcome: Disease free survival (DFS)

## Questions raised in the commentary

_Automated from the 30 newest of 31 indexed sources (May 2021 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice._

- Whether cisplatin and gemcitabine offer meaningful benefit in the adjuvant setting
- Whether the findings should change adjuvant treatment practice
- Which patients, if any, may benefit more from cisplatin and gemcitabine
- Whether new or biomarker-directed adjuvant strategies are needed

Also discussed: preserving first-line treatment options.

## Indexed commentary on ACTICCA-1 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 29
- Podcasts: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=acticca-1-nct02170090

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02170090", "email": "<work email>"}; the inbox owner confirms by the emailed link.